Business
GE HealthCare and Novo Nordisk to Collaborate to Advance Novel Non-Invasive Treatment for Type 2 Diabetes and Obesity with Ultrasound
Personalized peripheral focused ultrasound therapy has potential as non-invasive, non-pharmacological alternative for chronic disease management Encouraging
About this update from Ge Healthcare Technologies Inc.
[{"type":"text","content":"\n\nPersonalized peripheral focused ultrasound therapy has potential as non-invasive, non-pharmacological alternative for chronic disease management\n\n\n\nEncouraging pre-clinical and early clinical data indicate potential use for people with type 2 diabetes\n\n\n\nCollaboration pairs GE HealthCare expertise in ultrasound technology with Novo Nordisk long-term experience in metabolic disease treatment and management to develop solution to improve patient care\n\n\n\n CHICAGO--(BUSINESS WIRE)--\nGE HealthCare (Nasdaq: GEHC) today announced a collaboration with Novo Nordisk to further advance the clinical and product development of peripheral focused ultrasound (PFUS). This is a novel technology that has potential to specifically regulate metabolic function in the body using ultrasound that may support the treatment of chronic diseases such as type 2 diabetes and obesity.\n\n\nPFUS is a non-invasive type of bioelectronic medicine that uses ultrasound to activate the nervous system to stimulate a response that may be able to treat disease. Pre-clinical proof of concept and initial early-stage clinical research suggests that it may impact glucose metabolism in people with diabetes via personalized ultrasound stimulation of nerve pathways. If validated with further clinical evidence, PFUS could represent a non-pharmacologic approach to normalize blood glucose levels in people with type 2 diabetes. The existing technology was developed by a team of scientists at GE HealthCare’s HealthCare Technology and Innovation Center, formerly part of the GE Research Center.\n\n\n“In an era where diabetes is increasing around the globe, we are enthusiastic about the potential for ultrasound to help people live healthier lives,” said Roland Rott, President and CEO, Ultrasound, GE HealthCare. “This collaboration with Novo Nordisk opens a path to evolve ultrasound from a means of screening and diagnosis into therapy, as well. We are eager to validate and further develop this potentially groundbreaking science, as we strive to offer patients alternative treatment options for chronic diseases.”\n\n\nAn estimated 540 million adults around the world have diabetes, with type 2 diabetes accounting for more than 90 percent of cases.1 An estimated one in eight individuals will have diabetes in 2045, with significant disease burden in low-and-middle-income c...